섬유아세포 성장인자 시장 : 세계 산업 분석, 규모, 점유율, 성장, 동향 및 예측(2024-2031) - 제품, 용도, 최종 사용자, 지역 및 기업별
Fibroblast Growth Factors Market - Global Fibroblast Growth Factors Industry Analysis, Size, Share, Growth, Trends, and Forecast 2024-2031 - (By Product Coverage, By Application Coverage, By End User Coverage, By Geographic Coverage and By Company)
상품코드:1472053
리서치사:Fairfield Market Research
발행일:2024년 04월
페이지 정보:영문 185 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계 섬유아세포 성장인자(FGF) 시장 규모는 2024년 약 2억 8,000만 달러에서 2031년 5억 달러로 크게 확대될 것으로 예상되며, 급격한 성장세를 보일 것으로 예상됩니다. 이 시장은 2024년부터 2031년까지 8.64%라는 놀라운 CAGR로 확대될 것으로 예상됩니다.
2024년부터 2031년까지 시장 매출은 1.7배 이상 성장할 것으로 예상되며, 이는 다양한 치료 분야에서 수요와 채택이 증가함에 따른 것으로 분석됩니다.
FGF는 상처 치유, 조직 재생, 종양학, 피부과, 심혈관 질환, 신경 질환 등 다양한 분야에 적용되고 있으며, 여러 분야에서 급성장하고 있는 치료 가능성을 보여주고 있습니다.
FGF 시장의 확대는 의료비 지출 증가, 생명공학 기술 발전, 치료 분야에서의 응용 분야 확대 등 여러 요인에 의해 촉진되어 강력한 성장 궤도를 보이고 있습니다.
이 보고서는 세계 섬유아세포 성장인자 시장에 대해 조사했으며, 시장 개요와 함께 제품별/용도별/최종사용자별/지역별 동향, 시장 진출기업의 경쟁 동향 등을 조사하여 전해드립니다.
목차
제1장 주요 요약
제2장 시장 개요
시장 정의와 세분화
시장 역학
밸류체인 분석
Porter의 Five Forces 분석
COVID-19의 영향 분석
우크라이나·러시아 분쟁의 영향
경제 개요
PESTLE 분석
제3장 세계의 섬유아세포 증식인자 시장 전망, 2019년-2031년
세계의 섬유아세포 증식인자 시장 전망, 제품별, 금액(10억 달러), 2019년-2031년
세계의 섬유아세포 증식인자 시장 전망, 용도별, 금액(10억 달러), 2019년-2031년
세계의 섬유아세포 증식인자 시장 전망, 최종사용자별, 금액(10억 달러), 2019년-2031년
세계의 섬유아세포 증식인자 시장 전망, 지역별, 금액(10억 달러), 2019년-2031년
제4장 북미의 섬유아세포 증식인자 시장 전망, 2019년-2031년
제5장 유럽의 섬유아세포 증식인자 시장 전망, 2019년-2031년
제6장 아시아태평양의 섬유아세포 증식인자 시장 전망, 2019년-2031년
제7장 라틴아메리카의 섬유아세포 증식인자 시장 전망, 2019년-2031년
제8장 중동 및 아프리카의 섬유아세포 증식인자 시장 전망, 2019년-2031년
제9장 경쟁 구도
최종사용자별과 용도별 히트맵
기업의 시장 점유율 분석, 2023년
경쟁 대시보드
기업 개요
Thermo Fisher Scientific
Sigma-Aldrich(now part of Merck KGaA)
PeproTech
R&D Systems(a Bio-Techne brand)
Abcam
Cell Signaling Technology
Novus Biologicals
제10장 부록
LSH
영문 목차
영문목차
Global fibroblast growth factors (FGF) market is poised to experience a substantial surge, with projections indicating a remarkable expansion to US$500 million by 2031 from approximately US$280 million in 2024. This forecast reflects an impressive compound annual growth rate (CAGR) of 8.64% during the period spanning 2024 to 2031.
Significant Revenue Surge:
The market anticipates more than a 1.7x expansion in revenue between 2024 and 2031, propelled by increasing demand and adoption across various therapeutic applications.
Diverse Applications:
FGFs find applications in diverse fields such as wound healing, tissue regeneration, oncology, dermatology, cardiovascular diseases, and neurological disorders, showcasing burgeoning therapeutic potential across multiple sectors.
Growth Drivers:
Expansion in the FGF market is driven by several factors including increased healthcare expenditure, technological advancements in biotechnology, and widening applications across therapeutic areas, indicating a robust trajectory for growth.
Challenges:
Despite the promising outlook, the market faces challenges such as regulatory hurdles, safety concerns regarding adverse effects, and limited commercialization infrastructure, which require strategic solutions and collaborative efforts from industry stakeholders.
Industry Trends:
Notable trends shaping the FGF market include the rise of personalized medicine in oncology, collaborative research initiatives among industry players, and the exploration of expanded therapeutic applications beyond traditional indications.
Opportunities:
Exploring novel therapeutic applications and expanding into emerging markets, particularly in the Asia Pacific region, present significant growth opportunities for players in the FGF market.
Regional Insights:
North America leads the market, followed by Europe and the Asia Pacific, with the Rest of the World showing potential for growth, driven by evolving healthcare infrastructure and increasing adoption of advanced medical technologies.
Key Players:
Major industry players such as Amgen, Pfizer, and Johnson & Johnson dominate the market landscape, leveraging continuous research and development efforts, strategic partnerships, and innovative product development to maintain their competitive edge.
Notable Developments:
Recent noteworthy developments in the FGF market include Amgen's RegenFibra(TM) for diabetic foot ulcers, Pfizer's RejuvaGlow(TM) dermal filler, and Johnson & Johnson's orthopaedic implants distribution agreement, reflecting ongoing innovation and investment in the sector.
Key Growth Determinants:
Expansion of FGF applications across various therapeutic areas, continuous technological advancements in biotechnology, and the increasing healthcare expenditure Globally are key determinants fueling market growth.
Major Growth Barriers:
Stringent regulatory requirements, safety concerns related to adverse effects, and limited commercialization infrastructure pose significant barriers to the growth of the FGF market, necessitating proactive measures and collaborative efforts to address these challenges.
Key Trends and Opportunities to Look at:
Key trends such as the personalized medicine boom in oncology, collaborative research initiatives, and the exploration of expanded therapeutic applications present exciting opportunities for industry players to capitalize on.
Regional Frontrunners:
North America leads the Global FGF market, benefitting from established regulatory frameworks and high healthcare expenditure, followed by Europe and the Asia Pacific, which hold immense promise due to factors such as government funding for innovation and a rapidly aging population.
Fairfield's Competitive Landscape Analysis:
The FGF market is fiercely competitive, with industry leaders such as Thermo Fisher Scientific, Merck KGaA (formerly Sigma-Aldrich), PeproTech, and others dominating the landscape. Key growth strategies include product development, strategic partnerships, and market expansion initiatives.
Leaders in Global Fibroblast Growth Factors Space:
Leading companies in the Global FGF market include Thermo Fisher Scientific, Merck KGaA (formerly Sigma-Aldrich), PeproTech, R&D Systems (a Bio-Techne brand), Abcam, Cell Signaling Technology, and Novus Biologicals, among others.
Global Fibroblast Growth Factors Market Segmentation:
By Product:
FGF1
FGF2
FGF3
FGF4
FGF7
FGF10
FGF11
FGF12
FGF13
FGF14
FGF15
FGF18
FGF19
FGF20
FGF23
By Application:
Oncology
Hematology
Wound Healing
Dermatology
Cardiovascular Disease & Diabetes
Cell Culture
By End User:
Pharmaceutical and Biotechnology Companies
Research Centers & Academic Institutes
Contract Manufacturing Organizations (CMO) and Contract Development and Manufacturing Organizations (CDMO)
By Region:
North America
Latin America
Europe
East Asia
South Asia
Oceania
Middle East and Africa
Table of Contents
1. Executive Summary
1.1. Global Fibroblast Growth Factors Market Snapshot
1.2. Future Projections
1.3. Key Market Trends
1.4. Regional Snapshot, by Value, 2023
1.5. Analyst Recommendations
2. Market Overview
2.1. Market Definitions and Segmentations
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Market Opportunities
2.3. Value Chain Analysis
2.4. Porter's Five Forces Analysis
2.5. COVID-19 Impact Analysis
2.5.1. Supply
2.5.2. Demand
2.6. Impact of Ukraine-Russia Conflict
2.7. Economic Overview
2.7.1. World Economic Projections
2.8. PESTLE Analysis
3. Global Fibroblast Growth Factors Market Outlook, 2019 - 2031
3.1. Global Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
3.1.1. Key Highlights
3.1.1.1. FGF1
3.1.1.2. FGF2
3.1.1.3. FGF3
3.1.1.4. FGF4
3.1.1.5. FGF7
3.1.1.6. FGF10
3.1.1.7. FGF11
3.1.1.8. FGF12
3.1.1.9. FGF13
3.1.1.10. FGF14
3.1.1.11. FGF15
3.1.1.12. FGF18
3.1.1.13. FGF19
3.1.1.14. FGF20
3.1.1.15. FGF23
3.1.1.16. Others
3.2. Global Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
3.2.1. Key Highlights
3.2.1.1. Oncology
3.2.1.2. Hematology
3.2.1.3. Wound Healing
3.2.1.4. Dermatology
3.2.1.5. Cardiovascular Disease & Diabetes
3.2.1.6. Cell Culture
3.2.1.7. Others
3.3. Global Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
3.3.1. Key Highlights
3.3.1.1. Pharmaceutical & Biotechnology Companies
3.3.1.2. Research Centers & Academic Institutes
3.3.1.3. CMOs & CDMOs
3.4. Global Fibroblast Growth Factors Market Outlook, by Region, Value (US$ Bn), 2019 - 2031
3.4.1. Key Highlights
3.4.1.1. North America
3.4.1.2. Europe
3.4.1.3. Asia Pacific
3.4.1.4. Latin America
3.4.1.5. Middle East & Africa
4. North America Fibroblast Growth Factors Market Outlook, 2019 - 2031
4.1. North America Fibroblast Growth Factors Market Outlook, by Product, Value (US$ Bn), 2019 - 2031
4.1.1. Key Highlights
4.1.1.1. FGF1
4.1.1.2. FGF2
4.1.1.3. FGF3
4.1.1.4. FGF4
4.1.1.5. FGF7
4.1.1.6. FGF10
4.1.1.7. FGF11
4.1.1.8. FGF12
4.1.1.9. FGF13
4.1.1.10. FGF14
4.1.1.11. FGF15
4.1.1.12. FGF18
4.1.1.13. FGF19
4.1.1.14. FGF20
4.1.1.15. FGF23
4.1.1.16. Others
4.2. North America Fibroblast Growth Factors Market Outlook, by Application, Value (US$ Bn), 2019 - 2031
4.2.1. Key Highlights
4.2.1.1. Oncology
4.2.1.2. Hematology
4.2.1.3. Wound Healing
4.2.1.4. Dermatology
4.2.1.5. Cardiovascular Disease & Diabetes
4.2.1.6. Cell Culture
4.2.1.7. Others
4.3. North America Fibroblast Growth Factors Market Outlook, by End User, Value (US$ Bn), 2019 - 2031
